Vapogenix’s core technology (patents pending) is licensed from University of Texas M.D. Anderson Cancer Center. The licensed technology covers novel formulations of known medications through new routes of administration for new indications, with the aim of creating potent analgesic and anti-inflammatory drugs. The company’s lead product, VPX-595, is a compound being developed initially for the treatment of acute pain.